

### Remarks


In response to the written restriction requirement dated May 4, 2006, the applicant hereby elects Group I (vectors for anthrax protective antigen) and Group II (vectors for plague/*Yersinia pestis*) for further prosecution. The restriction requirement is traversed to the extent that the aprotinin protein of WO 00/03012, cited on page 3 of the restriction requirement, is not a "protective antigen" as the term is commonly used and as it is defined in paragraph 39, for example, of the subject published application (US 20050108792). As stated in paragraph 39, "By 'protective antigen' is meant that the antigen elicits an immunogenic response in mammals when administered by an appropriate route in an appropriate amount." WO 00/03012, itself, refers to aprotinin as a "pharmaceutical protein." Aprotinin is administered by injection to reduce bleeding during complex surgery. It inhibits several serine proteases.

With the foregoing noted, and as a default, the applicants hereby elect Group I (vectors for anthrax protective antigen).

Although it is believed that no fees are due in connection with this Election, the Commissioner is hereby authorized to charge any such fees to Deposit Account 19-0065.

The applicant invites the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Jay M. Sanders  
Patent Attorney  
Registration No. 39,355  
Phone No.: 352-375-8100  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

JMS/ehm

Attachments: 37 CFR §1.821 Submission of Substitute Sequence Listing  
Substitute Sequence Listing on Paper  
Substitute Sequence Listing in Computer Readable Form (disk)